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Dosage of pain rehabilitation programmes for patients with chronic
musculoskeletal pain: a non-inferiority randomised controlled trial
Michiel F. Renemana, Franka P. C. Waterschoota, Johannes G. M. Burgerhofb, Jan H. B. Geertzena, Henrica R.
Schiphorst Preupera and Pieter U. Dijkstraa,c
aDepartment of Rehabilitation Medicine, Center for Rehabilitation, University of Groningen, University Medical Center Groningen, The
Netherlands; bDepartment of Epidemiology, University Medical Centre Groningen, University of Groningen, The Netherlands; cDepartment of
Oral and Maxillofacial Surgery, University Medical Centre Groningen, University of Groningen, the Netherlands
ABSTRACT
Purpose: To analyse the effects of interdisciplinary pain rehabilitation programmes with different
dosages; care as usual versus short form.
Methods: A single blinded, two armed, randomised controlled trial, with non-inferiority design was
performed. All patients with chronic musculoskeletal pain referred to an outpatient multidisciplinary pain
rehabilitation programme were eligible for this study. Only dosage differed, content was similar. The dif-
ference on Pain Disability Index was the primary outcome measure. Four points difference on Pain
Disability Index was applied as a non-inferiority margin. Treatment effects within groups were expressed
in standardised mean difference and effect sizes were calculated between the groups.
Results: Because care as usual was frequently extended, the difference in dosage between groups was
limited. The study was stopped prematurely because of an a-priori stopping rule. Interim analyses are pre-
sented. Both groups (care as usual n¼ 58, short form n¼ 54) improved significantly (mean Pain Disability
Index change care as usual: 10.8; short form: 8.3). Mean difference between groups was 2.5 points
(95% confidence interval was 2.2 to 7.3). Effect size between groups was 0.2.
Conclusions: The 95% confidence interval for the difference in mean pain disability reduction exceeded
the upper limit of the non-inferiority margin. The results of the primary analyses of this trial are, therefore,
inconclusive. Ancillary analyses revealed that programme dosage was not associated with differences in
the disability outcomes.
 IMPLICATIONS FOR REHABILITATION
 Optimum dosage of interdisciplinary pain rehabilitation programs is unknown and scarcely studied.
This study is the first to analyse dosage as primary aim.
 Although results are inconclusive, they also suggest that differences in dosage may not automatically
lead to differences in effects.
 Further research is needed to analyse what dosage works for whom; to detect optimum effective and
cost-effective dosage of pain rehabilitation programmes.
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Introduction
Multidisciplinary pain rehabilitation programmes are recom-
mended for the patients with chronic low back pain [1]. Pain
rehabilitation programs aim to reduce disability, distress, and use
of health care services by means of education regarding physical,
psychological, and practical techniques to improve function, work
participation and health related quality of life [2]. Multidisciplinary
programmes have shown effectiveness for patients with chronic
musculoskeletal pain [1,3,4].
Across the pain rehabilitation centres nationally and internation-
ally, there is much diversity in content and dosage of pain rehabilita-
tion programs. Health care systems aim for the best treatments
based on available evidence. However, there is paucity of evidence
about the influence of dose on effects of these programs. In a recent
systematic review [5], no randomised controlled trials were identified
that were designed to analyse effects of differences in dose variables
on outcome of pain rehabilitation programs. Additionally, no studies
have been identified whose primary objective was to analyse the
association between dose and effect of pain rehabilitation program.
If optimal dosage is known, this may benefit patients and could
reduce direct or indirect costs. If similar effects are achieved with a
shorter program, this could lead to an earlier reduction of disability,
regaining quality of life, and participation in daily life happening
sooner. Shorter programmes may also minimise direct and indirect
costs associated with pain rehabilitation program. Employers could
also benefit from the earlier return to work for patients with work
productivity loss, rehabilitation centres can reduce waiting lists and
overall it can improve efficiency of care. Additionally, shorter pro-
grammes are also attractive for health care insurers and society as
a whole because of the reduction of direct and indirect costs.
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The aim of this study was to analyse the differences in effects
of pain rehabilitation programs with different dosages: care as
usual and short form in a non-inferiority design. Because large
pain rehabilitation program dosage variations exist, without evi-
dence that higher dosage leads to better results, we hypothesised
that short form will be non-inferior to care as usual in an out-
patient pain rehabilitation setting.
Methods
Design
The study was a single blinded, two armed, randomised controlled
trial, with a non-inferiority design [6]. The study took place at the
University Medical Centre Groningen, Department of Rehabilitation
Medicine, Centre for Rehabilitation, location Beatrixoord Haren.
The Medical Ethics Committee of the University Medical Centre
Groningen approved the study protocol (NL30094.042.11). Trial
registration: international clinical trials registry platform of World
Health Organization (Trial ID¼NTR3385).
CONSORT guidelines for reporting noninferiority and equiva-
lence randomized trials were used.
Operational definitions
Dosage contains both duration of the programme and number of
contact hours. Duration was defined as the total length of pain
rehabilitation program and is expressed in weeks. Contact hours
were defined as the total amount of hours that a patient spends
with therapist(s) during the program.
Participants
All patients with chronic musculoskeletal pain referred to an out-
patient pain rehabilitation program at the Centre for Rehabilitation,
University Medical Center Groningen, between September 2011 and
October 2013 were potential participants in this study. This centre
provides pain rehabilitation programs with a duration of 8, 12, 16 or
20weeks. Patients were eligible for the study when: (1) they were
admitted for a 12, 16 or 20week pain rehabilitation program; (2) they
had chronic musculoskeletal pain for more than three months with-
out a specific pathological care as usual se; (3) they experienced
chronic musculoskeletal pain induced disability; (4) social and psy-
chological factors were assumed to be relevant in maintaining
chronic musculoskeletal pain induced disability [2]; (5) they were will-
ing to stop other treatments for chronic musculoskeletal pain during
pain rehabilitation program (except pain medication); (6) they were
18years or older; (7) they were motivated to participate in pain
rehabilitation program and (8) they were willing to participate in the
study and signed an informed consent. Patients were excluded when
they: (1) were referred to the 8week pain rehabilitation program; (2)
were unable to understand the Dutch language; (3) had comorbid-
ities such as heart failure, rheumatoid arthritis, or psychiatric disor-
ders preventing a pain rehabilitation program.
Interventions
Common features of care as usual and short form
The objectives of care as usual and short form were the same and
the content was similar; both treatments were outpatient, interdiscip-
linary pain rehabilitation programs aimed to decrease chronic mus-
culoskeletal pain related disability, optimise participation, and
increase the quality of life. Pain rehabilitation program is intended to
coach patients to self-manage their pain and disability. The
rehabilitation team consisted of rehabilitation physicians, occupa-
tional therapists, physiotherapists, and psychologists. Pain rehabilita-
tion program was based on cognitive behavioural principles, and
consisted pain education, for example regarding differences between
acute and chronic pain. Patients were counselled to reflect on their
pain management strategies (avoiding pain) and how these strat-
egies could be changed into other management strategies (pain cop-
ing, alternating physical activity and rest and gradually increasing
activities). Each patient sets individual treatment goals. The rehabili-
tation physicians were responsible for the medical diagnosis, inter-
ventions (if any), pain education, reduction of pain medication, and
coordinated the overall treatment plan. Physiotherapists applied
exercise programmes and sports activities to improve patients’ confi-
dence in movement and reduce pain-related fear, improve activity
levels, and physical functioning. Occupational therapists assessed
current activities and patterns in daily living and educated patients
how activities could be changed into healthy activity levels (including
work participation) and patterns. Psychologists coached patients in
understanding and dealing with the social and emotional impact of
pain in daily life, pain beliefs, barriers for behaviour change, and
coached patients how to cope with pain.
After the rehabilitation physician considered a patient to be eli-
gible for pain rehabilitation program, the patient was invited for
an intake procedure, consisting of an interview by the rehabilita-
tion team (an occupational therapist, a physiotherapist and a
psychologist) and a questionnaire set [7]. The interviews were
aimed at admitting a patient to the program, and were used to
develop a treatment plan. If the patient was admitted to the pro-
gram, the patient’s team determined the required duration of 8,
12, 16 or 20weeks based on the assessment of the complexity of
the physical, social and personal situation of the patient, motiv-
ation, and ability to change behaviour. The team that determined
treatment duration consisted of professionals with on average
9 years of experience in pain rehabilitation. The program consisted
of occupational therapy sessions lasting 30min, two times a week,
physiotherapy sessions lasting 30 to 60min, two times a week,
and psychology sessions lasting 60min, once a week. The session
frequency of occupational therapy and physiotherapy was reduced
to once a week, and the psychology sessions were reduced to
once every 2weeks, thereby reducing contact hours by 50%. All
sessions were delivered in an individual setting. For clinical rea-
sons, the duration in weeks could be adapted (extended or short-
ened) in care as usual and in short form, depending on the
progression of the patient. Duration could be extended when add-
itional coaching was needed to decrease disability. Duration was
shortened when treatment goals were achieved earlier than
expected, when the patient demonstrated continued lack of pro-
gress, or when the patient stopped the treatment, because it did
not match the patient’s expectations or for reasons not related
to the programme (for instance holidays). Extending or shortening
the duration was based on agreement between the patient and
the team and decided by the rehabilitation physician. Reasons for
extending or shortening were registered.
The difference between care as usual and short form was the
duration (in weeks) and contact hours of pain rehabilitation pro-
gram proposed to the patients after the randomisation procedure.
Patients allocated to the care as usual group received 12, 16 or
20weeks of pain rehabilitation program as proposed after the
intake procedure. Patients allocated to the short form group
received a pain rehabilitation program that was 4weeks shorter
than proposed (which will result in approximately 10 contact
hours less on average). Thus, patients in short form received
4weeks/10 contact hours less than proposed after intake.
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Outcomes
The primary outcome variable was the difference in self-reported
disability assessed at baseline (T0) and 1–3weeks after discharge
(T1) with the pain disability index (PDI) [8]. The questionnaire con-
sists of seven items related to work, leisure and activities of daily
life. Each item is scored on an 11-point scale (0 indicating no dis-
ability and 10 indicating maximum disability). The total scale
ranges from 0 to 70. The PDI has been validated in different
patient groups [9]. Test–retest reliability is high (ICC¼ 0.91) [10].
Minimal Clinically Important Change of PDI is 8.5 points for sub-
scale “self-care” and 9.5 points for subscale “complaints” [11].
The secondary outcome variable, quality of life, was measured
with the Euroqol 5D-5L [12] (EQ5D-5L; scale range 0.329 to
1.000) [13]. The EQ-5D-5L assesses five dimensions (mobility, self-
care, usual activities, pain/discomfort, anxiety/depression) of
health on a 5-point scale: no problems, slight problems, moderate
problems, severe problems, and extreme problems. The overall
health is assessed on a 0–100 visual analogue scale of 20 cm
(EQ-5D-VAS). A higher score indicates a better overall state of
health. The minimal clinically important difference was 10.5 points
for the EQ-5D VAS and 0.03 points for the five dimensions of the
EQ-5D-3L [14]. The EQ-5D-5L version is based on the EQ-5D-3L
version. The 5 L version demonstrates improved discriminatory
power [15], but the minimal clinically important difference for this
version has not yet been examined.
Patient characteristics gender, age, marital status, educational
level, work status, and welfare status, as well as pain status (loca-
tion, pain duration and worst and average pain in the last week)
were assessed at baseline. PDI and EQ-5D-5L were assessed at
baseline (T0), 1–3weeks after program completion (T1) and at
3months and 1 year. This paper reports short term results (T1).
Sample size
Sample size was calculated using the group sequential non-infer-
iority criterion. The standard deviation (SD) on PDI scores in care
as usual was 11. The non-inferiority margin was calculated as 40%
of the mean change on PDI scores in care as usual, which was 10
points, and thus the non-inferiority margin was set at 4 points.
For group sequential non-inferiority design, an overall alpha of
0.05 and power of 0.8 was used. Using Power Analyse and
Sample Size, version 11 software, these data gave an estimation
of 124 patients needed per arm and 248 patients in total.
Including 10% drop-outs, 276 patients should be included for
the study.
Randomisation
After determination of program duration by the team and after
obtainment of informed consent, patients were sequentially and
randomly assigned to the two groups by an independent person.
Patients were stratified on work status (paid work or unpaid/no
work), resulting in two strata. For each stratum, blocks of six were
used. Randomisation was generated by using a computer random
generator. Sequentially numbered, sealed, opaque envelopes
were used for each stratum.
Blinding
Patients were blinded for allocation. Before inclusion, they were
informed about the duration of care as usual, which could be 8,
12, 16 or 20weeks. It was explained to patients that a duration
was proposed by the team based on the assessment results.
Furthermore, they were informed about the experiment of four
weeks shortened duration. They were unaware of the treatment
duration they were supposed to receive in care as usual, and,
therefore, they were blinded for allocation to care as usual or
short form. Patients were an outcome assessor for outcome meas-
urements since they filled in the PDI and other questionnaires.
They were blinded for T0 scores. Clinicians could not be blinded
for intervention for the 20weeks duration because this part only
exists in the care as usual group.
Analyses
An interim analysis was planned halfway the inclusion period. This
would enable us to recalculate the a priori sample size based on
trial data, as opposed to assumptions (a priori). Additionally,
based on a-priori stopping rules, it was decided that the trial
would be stopped if more than 25% of the pain rehabilitation
programs in the short form were extended or if the decrease in
means on PDI was 4 points larger in care as usual compared to
care as usual short form. Differences in mean PDI scores were
tested by a one-sided t-test. In consultation with a statistician, it
was decided a priori to split the alpha of 0.05 in 0.005 for the
interim analysis, and 0.045 for final analyses. Because the study
was stopped preliminarily, however, only one analysis was per-
formed for which we used a two-sided 95% confidence interval
(CI) approach.
Distribution of variables was assessed for normality. Based on
data distribution appropriate parametric or non-parametric statis-
tics were used.
Means and SD’s of primary outcome are presented for care as
usual and short form group. Statistical analyses included intention
to treat analyses for primary outcomes. A CI approach was used
to interpret non-inferiority (Figure 1). In the intention to treat
analyses an independent sample t-test was used to analyse differ-
ences in changes between the groups regarding PDI and EQ-5D-
5L scores. Based on these results 2-sided 95% CIs were calculated.
Non-inferiority was established when the upper or lower limit of
the 95%CI of the mean difference would not exceed the non-
inferiority limits of 0 and 4 (Figure 1). Treatment effects within
groups were expressed in standardised mean difference (SMD):
(meanchange/SDchange). Effect sizes (ES) were calculated between
groups (meanchange intervention group - meanchange control group)/
SDPooled [16]. Interpretation of SMD and ES: <0.10 no effect;
0.10–0.30 little effect; 0.30–0.50 moderate effect; 0.50–0.80 large
effect; >0.80 very large effect [17].
Ancillary analyses
Because the duration of the programs was similar between
groups, a regression analysis was performed to analyse predictors
of results, a per protocol analysis. The dependent variable was
change in disability (PDI T1-T0). Independent variables were: PDI
baseline, pain rehabilitation program duration (weeks) and con-
tact hours, gender, average pain at baseline and interaction term
of gender and duration (weeks). Residuals were checked for nor-
mal distribution. Because in some patients the program was
shortened and in some the program was extended, we explored
differences in baseline characteristics and trial results between
patients with a shortened program, with a program as planned
and patients with an extended program using Chi-square analyses
and ANOVA, and regression analyses.
All statistical analyses were performed in SPSS soft-
ware version 22.
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Results
Patient characteristics and trial flow
Between September 2011 and October 2013, 694 patients were
admitted. A total of 257 patients (37%) were eligible for this study
and signed an informed consent. Reasons of patients for non-par-
ticipation were for example: misunderstandings regarding plan-
ning, trial participation was of low priority and, consequently,
patients forgot to sign the informed consent, and unwillingness
to participate in the trial. Interim analyses revealed that in 36% of
the patients in short form was extended and 24% in care as usual.
Based on the a priori stopping rules, the study was stopped
immediately after the interim analyses. At that point, n¼ 201
(n¼ 102 care as usual, n¼ 99 care as usual short form) patients
had been randomised (Figure 2). In accordance with the rules of
the METC, 30 patients who were enrolled in the trial were given
the possibility to receive the admitted treatment duration and
were excluded from analyses. In total 153 patients completed the
program, of which n¼ 81 in care as usual and n¼ 72 in care as
usual short form. Analyses were performed for patients with com-
plete datasets: n¼ 58 in care as usual and 54 in care as usual
short form. The majority of patients experienced pain for more
than one year at baseline. The most prevalent diagnoses were
chronic back pain (42%), chronic neck pain (19%), widespread
pain (9%) and fibromyalgia (7%). Some patients reported several
pain sites. Patients who completed the study differed significantly
on work status and welfare status, compared to those who did
not complete the study (Table 1).
Main outcomes
The reduction of PDI scores was 2.5 points larger in the care as
usual group compared to the short form group (Figure 1). The
mean difference of 2.5 points lies within the non-inferiority mar-
gin from 0.0 to 4.0. Because the CI of this difference exceeded the
upper and lower limit of the non-inferiority margin, the results
were inconclusive.
After excluding the drop-outs, in 67% of the cases, pain
rehabilitation programs were delivered as planned or shorter, and
in 33% of the cases pain rehabilitation programs were extended
(Table 2: short form 22%; care as usual 12%). Differences in dos-
age between shortened, as planned, and extended programs
were non-significant (p¼ 0.066). Reasons for extending were for
example: changes in the behaviour or situation of the patient,
return to work assistance needed more support and/or more time
than anticipated, the patient case was more complex than esti-
mated a priory, and treatment logistics.
Both groups improved significantly over time. SMD and ES for
PDI and EQ5D scores are presented in Table 3. Differences in
results were not significant (p> 0.05) between groups for both
outcome measures.
Ancillary analyses
Dosage or any of the other variables did not significantly contrib-
ute to the regression model with response variable change in PDI
(results not presented). The mean duration of the program for the
group with a program as planned was 10.0 (SD 3.8) weeks.
The mean number of contact hours was 27.1 (SD 9.7). For the
extended group the mean duration was 15.0 (SD 3.3) weeks, and
39.2 (SD 8.9) contact hours (Table 4). SMD of PDI of the group
with a program as planned was 0.9; ES of the extended subgroup
was 0.6. Differences between groups in baseline characteristics
(duration of program, shortened, as planned, and extended) were
insignificant, and none of the baseline variables contributed sig-
nificantly to a regression model with response variable change
duration (planned versus shortened, planned versus extended
(Table 5).
Adverse events








Superior Equivalent Non Inferior Inferior 
2.5 -2.2 7.3 
C1 
Figure 1. Illustration of the phenomenon of non-inferiority testing. The dotted double sided arrows represent the theoretical widths of the Confidence Intervals
(CI) of the differences in means between the experimental group and control group. If the CI lies left of 0: (A) the experimental group is superior to the control group.
If CI lies left of 4 (B1, B2, B3) the experimental group is non-inferior. If CI includes 4 (C2) non-inferiority is inconclusive. If CI lies is right to four the experimental group
is inferior (D). The results of the current study resulted in solid double sided arrow C1 with 95% confidence intervals for 2.2 to 7.3: which means non-inferiority is
inconclusive.
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Discussion
Results of this study were based on interim analyses because of
preliminary termination and should be interpreted with care. The
statistical analyses showed a mean difference in PDI change
between groups of 2.5 with CI from 2.2 to 7.3, which means
that the result of this non-inferiority trial was inconclusive. Within
both groups, short term ES were moderate to large for the out-
come measures disability and quality of life. In 25% of all cases
the duration of pain rehabilitation program could be reduced.
Because of extension of pain rehabilitation program in patients
randomised to short form and a limited sample size, this study was
not able to detect the differences in dosage or effect between the
two groups. The results could imply that shortening duration may
be considered in some cases without loss of short term results. A
lower dosage may benefit patients and other stakeholders.
However, the duration of 26% of all programs (36% within short
form and 17% within care as usual) was extended to achieve a
desired outcome. Extending (and shortening) of the program was
always agreed upon by the patients and the team and was a result
of a goal shift between baseline and later during progression of
the program. In our study, it was not possible to identify character-
istics of patients whose programs were extended or shortened, and
thus to plan a correct dosage at the start. This topic should be sub-
ject to further investigation. The results of the extended subgroup
were similar to those of the as planned group, indicating on the
one hand that extension of treatment might not be a solution to
improve treatment outcome, while on the other hand this can also
be interpreted positively: results might not have been achieved
without an extension. An in-depth study design with multiple
interim measurements would be recommended for further analyses
on this issue. Significant differences in baseline characteristics
between completers and drop-outs may be assumed to be caused
by differences in motivation of patients with disability compensa-
tion to complete treatment. However, characteristics of dropouts
have not been a subject of this study. It is unknown whether this
has systematically influenced the results of this study.
Because this trial is the first of its kind analysing dosage of
pain rehabilitation, the results of this trial cannot be compared to
other pain rehabilitation trials with similar designs. Patient charac-
teristics such as pain disability, pain intensity, pain duration, and
gender distribution, appear similar to other pain rehabilitation
program trials, both in the Netherlands and internationally [5],
and regular clinical secondary and tertiary rehabilitation
programmes in the Netherlands. Dosage of pain rehabilitation
program in this study was “midrange” when compared to dosage
reported in other studies [18]. The results of this study stress
the relevance of further dosage studies in different settings [5].
One of the main challenges expressed in pain rehabilitation is the
issue of “what works for whom.” We suggest adding another chal-
lenge: “how much works for whom?” Within pain rehabilitation,
this may apply to the multidisciplinary programme as a whole,
but also to its components. This question may open a new line of
Assessed for eligibility 
(n=257) 
Excluded (n=56) 
♦   Not meeting inclusion criteria (n=43) 
♦   Excluded because stop trial (n=13) 
Randomised (n=201) 
Analysed (n= 81) 
Drop out (n=22) 
Analysed (n=72) 
Drop out (n=11)  
Allocated to short form (n=99) 
♦ Received allocated intervention (n=72) 
♦ No discharge measurement (n=12) 
  Administrative error (n=5)  
Patient declined to start (n=2) 
Early drop-out (n=5) 
♦ Excluded: premature stop trial (n=14) 
♦ Declined to participate in trial (n=1) 
Allocated to care as usual (n=102) 
♦ Received allocated intervention (n= 81) 
♦  No discharge measurement (n= 5) 
Patient declined to start (n=4) 
Early drop-out (n=1) 





Figure 2. Flow diagram.
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research that may lead to major new insights. Because dosage
has been a methodological blind spot in pain rehabilitation
research, and dosage variables were defined and interpreted
differently across studies, results of previous trials may have been
biased by lack of control of dosage. If A is compared to B and
A leads to superior results, it is expected that A is the treatment
of choice. However, theoretically, if the dose of A was higher
than B, the difference also might be explained by dosage of
B [19]. Differences in dosage could also explain differences
between studies and could be a reason why some studies
were not able to detect significant differences between
interventions [18].
Weaknesses and strengths
A weakness of the study was that it had to be discontinued pre-
maturely because too many programs in de short form group
were extended. This caused lack of included patients and lack of
Table 2. Treatment duration and differences in dosage between groups.
Care as usual n¼ 81 Short form n¼ 72 p 95% CI
Received duration (weeks) (mean, SD) 11.7 (4.5) 10.8 3.9 0.323 0.5 to 2.2
Received contact hours (mean, SD) 30.7 11.3 29.8 10.4 0.622 2.7 to 4.4
Dropouts (n, %) 22 27% 11 15%
Weeks (mean, SD) 6.0 3.7 5.1 2.2
Shortened (n, %) 23 39% 15 25%
Weeks (mean, SD) 5.7 4.0 3.4 2.6
As planned (n, %) 22 37% 20 33%
Extended (n, %) 14 24% 26 42%
Weeks (mean, SD) 2.9 2.0 4.0 2.0
SD: Standard deviation; CI: Confidence interval.% of total n¼ 153.valid % of completers n¼ 120.
Table 1. Baseline characteristics of participants in care as usual and short form and participants who completed the study and those who did not.
Care as usual n¼ 81 Short form n¼ 72 Completers n¼ 120 Drop-outs n¼ 33
Mean n SD % Mean n SD % Median n IQR % Median n IQR %
Age (years) (n¼ 153) 43.8 12.4 44.1 11.9 44.6 33.6–52.3 47.4 40.4–54.9
Average pain last week (n¼ 153) 6.5 1.6 6.9 1.6 7.0 6–8 7.0 5.0–8.0
Worst pain last week (n¼ 153) 7.8 1.6 8.3 1.3 8.0 7–9 8.0 7–9
Gender (% female) (n¼ 153) 45 55.6 49 68.1 79 66 15 45
Duration of pain (n¼ 131)
3 months to 1 year 15 23.1 20 30.3 27 25.7 8 30.8
>1 year 50 76.9 46 69.7 78 7.3 18 69.2
Assigned treatment duration (weeks) (n¼ 153)
8 0 0.0 26 36.1 23 19.2 3 9.1
12 37 45.7 45 62.5 66 55.0 16 48.5
16 41 50.6 1 1.4 30 25.0 12 36.4
20 3 3.7 0 0.0 1 0.8 2 6.1
Marital status (n¼ 132)
Single 9 13.6 11 16.7 16 15.2 4 14.8
Married/living (apart) together 53 80.3 47 71.2 77 73.3 23 85.2
Otherwise 4 6.1 8 12.1 12 11.4 0 0.0
Education (n¼ 136)
No or low education 20 29.4 13 19.1 25 22.9 8 29.6
Middle education 30 44.1 34 50.0 51 46.8 13 48.1
High education 18 26.5 21 30.9 33 30.3 6 22.2
Work status (n¼ 135)
Employed, fulltime 19 27.5 20 30.3 34 31.8 5 17.9
Employed, part-time 22 31.9 18 27.3 36 33.6 4 14.3
Houseman/-wife 9 13.0 8 12.1 9 8.4 8 28.6
Unemployed 8 11.6 8 12.1 12 11.2 4 14.3
Otherwise 11 15.9 12 18.2 16 15.0 7 25.0
Benefit status (n¼ 135)
Not working and no benefit status 25 36.8 23 34.3 43 40.2 5 17.9
Partial sick leave/disability pension 30 44.1 30 44.8 40 37.4 20 71.4
Full sick leave/disability pension 6 8.8 9 13.4 14 13.1 1 3.6
Unemployed 4 5.9 0 0.0 4 3.7 0 0.0
Otherwise 3 4.4 5 7.5 6 5.6 2 7.1
Pain location (n¼ 153)
Head or face 16 9.5 21 12.8 31 11.8 6 8.5
Upper extremities 21 12.4 16 9.8 27 10.3 10 14.1
Neck or shoulders 38 22.5 39 23.8 59 22.5 18 25.4
Low back 47 27.8 45 27.4 75 28.6 17 23.9
Lower extremities 32 18.9 33 20.1 50 19.1 15 21.1
Otherwise 15 8.9 10 6.1 20 7.6 5 7.0
Number of pain sites (median, IQR) 2.0 1–4 2.0 1–4 2.0 1–4 3.0 1–3
SD: standard deviation; IQR: interquartile range; n: number of available participants/observations.Significant difference between care as usual and short form (p< 0.05).Significant difference between completers and drop-outs (p< 0.05).Pain sites: some patients reported several pain sites thus exceeding the number of participants.
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contrast regarding dosage between the care as usual and short
form groups, which may partly explain the inconclusiveness of
the results. In addition, the small sample size caused a relative
wide 95% CI, which also led to inconclusiveness. Different scen-
arios were considered and discussed with the team to shorten
the program. Care as usual was offered in programmes of 8,12,16
and 20weeks. In absence of evidence, it was decided to test
shortening with one step (4weeks). This could be considered a
methodological weakness of the study because the relative
impact differed between programmes (from 12 to 8weeks: 33%
reduction, 16 to 12weeks: 25% reduction, 20 to 16weeks: 20%
reduction). On the other hand, adherence to care as usual
strengthened this study because it reduced the risk of allocation
bias in patients and rehabilitation team members.
Extension of treatment duration may be regarded as a limita-
tion or even as an adverse event or programme violation.
However, during this study, we were obliged to adhere to the
Dutch health care regulations and the Medical Ethics Committee.
As a consequence, we were not allowed to deny health care that
was deemed necessary for good patient care. Within the field of
pain rehabilitation there are no guidelines regarding dosage. As
described in the introduction, pain rehabilitation programs aim to
reduce disability and use of health care services. Patients are
coached to self-manage pain and disability. As far as we know
there are no published validated measures to assess these self-
management skills. Consequently, it is unclear at what point a
patient will be ready to self-manage his pain and disability, and
when pain rehabilitation program is no longer of added value.
Partly because of lack of evidence regarding dosage of pain
rehabilitation program, choices of dosage are unclear and arbi-
trary. This may result in differences in dosage between and within
pain rehabilitation programs. This is a weakness of this study
because, in some cases this resulted in shortening or extending
pain rehabilitation program in both the care as usual and short
Table 3. Trial results based on intention to treat analysis of PDI scores and EQ5D scores between and within treatment groups.
n T0 Mean (SD) n T1 Mean (SD) n Difference in means (SD) 95% CI SMD
PDI total 144 37.0 (13.3) 119 25.8 (16.2) 112 9.6 (12.8) 7.2 to 12.0 0.8
Care as usual 74 36.1 (12.5) 63 25.1 (15.0) 58 10.8 (13.2) 7.3 to 14.3 0.8
Short form 70 37.9 (14.2) 56 26.6 (17.7) 54 8.3 (12.2) 5.0 to 11.6 0.7
ES between group difference 0.20
EQ5D index total 125 0.55 (0.20) 101 0.70 (0.18) 93 0.13 (0.17) 0.09 to 0.17 0.8
Care as usual 66 0.56 (0.19) 54 0.70 (0.17) 51 0.11 (0.19) 0.06 to 0.17 0.6
Short form 59 0.54 (0.21) 47 0.70 (0.20) 42 0.15 (0.15) 0.10 to 0.19 1.0
ES between group difference 0.19
EQ5D VAS 126 54.0 (17.7) 102 67.6 (17.3) 93 14.0 (18.8) 17.8 to 10.1 0.7
Care as usual 68 54.5 (17.8) 54 67.5 (16.1) 52 14.0 (20.7) 19.6 to 8.3 0.7
Short form 58 54.4 (17.7) 47 67.6 (18.7) 41 14.0 (17.0) 19.3 tot 8.6 0.8
ES between group difference 0
T0: before program; T1: direct after program.
PDI: Pain Disability Index (scale 0–70); EQ5D: Euroqol 5D index (scale 0.0–1.0); VAS: visual analog scale (0–100).
SD: Standard deviation, CI: Confidence interval.
SMD: Standardised mean difference; ES: Effect Size.
n: number of available observations.Paired observations.
Table 4. Differences between subgroups of patients, who completed the trial, according to duration of pain rehabilitation program; shortened, as planned
and extended.
Shortened As planned Extended
n Mean (SD) n Mean (SD) n Mean (SD) F value and p value
PDI T0 65 37.6 (14.0) 42 39.5 (11.0) 37 33.0 (14.0) F2,141¼ 2.515, p¼ 0.085
PDI T1 43 26.8 (15.9) 38 27.6 (16.6) 38 22.8 (16.2) F2,116¼ 0.956, p¼ 0.387
PDI T0–T1 39 8.1 (12.1) 38 11.4 (9.9) 35 9.4 (16.0) F2,109¼ 0.640, p¼ 0.529
PDI: Pain Disability Index (scale 0–70).
PDI T0: PDI score baseline, PDI T1: PDI score discharge.
PDI T0–T1: Differences between T0 and T1.
SD: Standard deviation; n: number of available observations.








Mean SD (M) Mean SD (M) Mean SD (M) Significance
Age 45.3 14.1 (0) 41.1 12.2 (0) 42.8 11.3 (0) F2,117¼ 0.972 p¼ 0.381
Average pain last week 6.5 1.8 6.9 1.4 6.6 1.5 (4) F2,102¼ 0.452 p¼ 0.638
Worst pain last week 7.9 1.8 8.3 1.3 7.9 1.4 (2) F2,105¼ 0.660 p¼ 0.519
PDI T0–T1 35.5 13.5 39.5 11 33.0 14.0 (3) F2,111¼ 2,569 p¼ 0.081
n % n % n %
Gender (% female) 28 73.7 29 69.0 22 55.0 X2¼ 3.321 p¼ 0.190
Duration of pain (2) (6) (4) X2¼ 2.175 p¼ 0.337
3 months to 1 year 4 12.1 3 8.3 1 2.8
>1 year 29 87.9 33 91.7 35 97.2
PDI T0–T1: Differences between T0 and T1; SD: Standard deviation.
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form groups. On the other hand, this is an important reason for
future research to focus on the rationale underlying dosage of
pain rehabilitation program, including transparency of choices in
dosage of treatment. This should eventually lead to more rational
dosage of pain rehabilitation programs, including explicit argu-
ments on which the choice of dosage for individual patients is
based and result in development of validated measurements to
determine program dosage.
A non-inferiority margin is chosen as the smallest value that
would be a clinically important effect [20]. Based on the mean
change of care as usual (10 points; near the 8.5–9.5 points of the
MCIC) we a priori defined that a margin of 40% of 10 points of
change (4 points), could be considered as similar. We acknowledge
that this is an arbitrary margin, however, conducting the first study
of this kind in our field, we could not build on guidelines, clinical
evidence or consensus statements, which means that other margins
would also be debatable. Only 76% of the randomized patients
were included in the ITT analyses, which might have potentially
introduced a bias in the results. We judge it as unlikely, because
there is no indication of systematic differences between the groups.
A strength of this study is the pragmatic, clinical design; includ-
ing the struggle of clinical practice regarding dosage of pain
rehabilitation programs. This study shows results of shortening and
extending pain rehabilitation programs. Based on the regression
analyses, which showed that dosage did not significantly contribute
to the model, extending does not directly lead to better results, nor
does reducing pain rehabilitation program directly leads to worse
results. As this was the first trial within pain rehabilitation to study
dosage, we suggest replication in different settings, and that all
future trials and observational studies in this field clearly describe
dosage issues to enable future (meta-)analyses of trial results.
Because the CI of the mean difference exceeded the upper and
lower limit of the non-inferiority margin, the results of this trial are
inconclusive. In this study, a reduction of four weeks of pain
rehabilitation program did not lead to non-inferior mean results.
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